Keywords: Dendreon, Provenge, Prostate cancer, Medicare coverage, USA, CMS

USA’s CMS to cover infusion costs associated with Dendreon’s Provenge

Article | 21 November 2011

Print This

Sales of Dendreon’s (Nasdaq: DNDN) new prostate cancer treatment Provenge (sipuleucel-T) have been disappointing so far, partly as ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in